Donenberg Phillip B. 4

What Happened

• Phillip B. Donenberg, a director of Sensei Biotherapeutics (SNSE), was granted a derivative award on 2026-06-10 covering 12,500 shares. The filing reports an acquisition type "A" (award/grant) at $0.00 per share (i.e., no cash paid at grant). The instrument is described in the filing footnote as an option that becomes exercisable as it vests.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely within the usual two-business-day window).
• Transaction type/code: Award/Grant (A); derivative security (option) for 12,500 shares; reported price $0.00; total reported value $0.
• Vesting: 12 equal monthly installments over one year, fully vested on June 10, 2027, subject to Donenberg’s continuous service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing exhibits/remarks: Exhibit 24 — Power of Attorney noted.
• No indication the shares were immediately exercised or sold.

Context

• This is a compensation-related option/grant to a director (not a sale or open-market purchase). Such awards are common for board compensation and do not by themselves signal a buy/sell intent. The option vests over 12 months, so any future exercise or sale would be reported separately.